Feng Huapeng, Yamashita Makoto, da Silva Lopes Tiago Jose, Watanabe Tokiko, Kawaoka Yoshihiro
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States.
Front Microbiol. 2019 Jan 24;10:19. doi: 10.3389/fmicb.2019.00019. eCollection 2019.
Influenza outbreaks can be either seasonal or pandemic. Vaccination is an effective strategy to control influenza; however, the efficacy of the currently available inactivated influenza virus vaccines is suboptimal, especially in the elderly. Vaccine efficacy can be improved by the addition of adjuvants, but few adjuvants have been approved for human vaccines. To explore novel, safe, and effective adjuvants for influenza vaccines, here we used a mouse model to screen 46 injectable drug additives approved in Japan. Of these 46 candidates, we identified 20 compounds that enhanced the efficacy of the split influenza HA vaccine against lethal virus challenge. These 20 compounds included 15 novel adjuvant candidates and 5 compounds with previously reported adjuvant effects for other antigens but not for influenza vaccine. Given that these additives are already approved for human use, the hurdle for their clinical use as novel and effective adjuvants for influenza or other vaccines is lower than for other adjuvant candidates whose safety profiles are unknown.
流感爆发可以是季节性的，也可以是大流行的。接种疫苗是控制流感的有效策略；然而，目前可用的灭活流感病毒疫苗的效力并不理想，尤其是在老年人中。通过添加佐剂可以提高疫苗效力，但很少有佐剂被批准用于人类疫苗。为了探索用于流感疫苗的新型、安全且有效的佐剂，我们在此使用小鼠模型筛选了46种在日本被批准的注射用药物添加剂。在这46种候选物中，我们鉴定出20种化合物，它们增强了裂解流感血凝素疫苗对致死性病毒攻击的效力。这20种化合物包括15种新型佐剂候选物以及5种对其他抗原具有先前报道的佐剂效应但对流感疫苗没有佐剂效应的化合物。鉴于这些添加剂已被批准用于人类，将它们用作流感或其他疫苗的新型有效佐剂的临床应用障碍低于那些安全性未知的其他佐剂候选物。
